Global Blood Therapeutics Revenue Growth Rates (GBT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Global Blood Therapeutics Inc.  (NASDAQ: GBT)
 

GBT's Revenue Growth by Quarter and Year

Global Blood Therapeutics's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GBT Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September -
2nd Quarter June 71.55
1st Quarter March 55.16
FY 126.71





GBT Revenue second quarter 2022 Y/Y Growth Comment
Global Blood Therapeutics Inc. reported Revenue rise of 50.44% year on year in the second quarter 2022, to $ 71.55 millions, this is lower than Global Blood Therapeutics Inc.'s recent average Revenue surge of 322.17%.

Looking into second quarter 2022 results within Major Pharmaceutical Preparations industry 85 other companies have achieved higher Revenue growth. While Global Blood Therapeutics Inc.' s Revenue jump of 50.44% ranks overall at the positon no. 873 in the second quarter 2022.


GBT Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - 35.84 % 1857.35 % -
3rd Quarter September - 41.1 % - -
2nd Quarter June 50.44 % 50.98 % - -
1st Quarter March 41.29 % 176.49 % - -
FY   - 57.3 % 5767.77 % -

Financial Statements
Global Blood Therapeutics's second quarter 2022 Revenue $ 71.55 millions GBT's Income Statement
Global Blood Therapeutics's second quarter 2021 Revenue $ 47.56 millions Quarterly GBT's Income Statement


GBT Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - 7.78 % 11.95 % -
3rd Quarter September - 9.44 % 17.11 % -
2nd Quarter June 29.71 % 21.82 % 123.09 % -
1st Quarter March -1.68 % -5.47 % 569.19 % -
FY (Year on Year)   - 57.3 % 5767.77 % -


Back to GBT Growth rate Comparisons >> Back to GBT Growth rate Comparisons >>


Revenue second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #86
Healthcare Sector #172
Overall #873

Revenue Y/Y Growth Statistics
High Average Low
1858.97 % 322.17 % 35.85 %
(Dec 31 2020)   (Dec 31 2021)
Revenue second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #86
Healthcare Sector #172
Overall #873
Revenue Y/Y Growth Statistics
High Average Low
1858.97 % 322.17 % 35.85 %
(Dec 31 2020)   (Dec 31 2021)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Global Blood Therapeutics's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
569.73 % 78.35 % -5.45 %
(Mar 31 2020)  


GBT's II. Quarter Q/Q Revenue Comment
Global Blood Therapeutics Inc. achieved in the II. Quarter 2022 below company average Revenue jump of 29.71% quarter on quarter, to $ 71.55 millions.

Although the II. Quarter 2022 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 21.82% growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 83 other companies have achieved higher Revenue quarter on quarter growth. While Global Blood Therapeutics's Revenue growth quarter on quarter, overall rank is 725.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #84
Healthcare Sector #153
Overall #725
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #84
Healthcare Sector #153
Overall #725
Revenue Q/Q Growth Statistics
High Average Low
569.73 % 78.35 % -5.45 %
(Mar 31 2020)  


GBT's II. Quarter Q/Q Revenue Comment
Global Blood Therapeutics Inc. achieved in the II. Quarter 2022 below company average Revenue jump of 29.71% quarter on quarter, to $ 71.55 millions.

II. Quarter 2022 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 21.82% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 83 other companies have achieved higher Revenue quarter on quarter growth. While Global Blood Therapeutics's Revenue growth quarter on quarter, overall rank is 725.


Global Blood Therapeutics's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)
Cumulative Revenue 12 Months Ending $ 234.86 $ 210.87 $ 194.75 $ 179.95 $ 164.78
Y / Y Revenue Growth (TTM) 42.53 % 41.78 % 57.31 % 112.66 % -
Year on Year Revenue Growth Overall Ranking # 350 # 420 # 321 # 79 # 0
Seqeuential Revenue Change (TTM) 11.38 % 8.28 % 8.23 % 9.2 % 10.79 %
Seq. Revenue Growth (TTM) Overall Ranking # 2109 # 815 # 662 # 799 # 791


Cumulative Revenue growth Comment
Although Global Blood Therapeutics's Annual Revenue growth year on year were below company's average 63.57% , Revenue announced in the Jun 30 2022 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 42.53% year on year, from 41.78% in Mar 31 2022.

In the Healthcare sector 74 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 350, from total ranking in previous quarter at 420.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 112
Healthcare Sector # 75
Overall # 350

Revenue TTM Y/Y Growth Statistics
High Average Low
112.66 %
 63.57 %
41.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 112
Sector # 291
S&P 500 # 2109
Cumulative Revenue growth Comment
Although Global Blood Therapeutics's Annual Revenue growth year on year were below company's average 63.57% , Revenue announced in the Jun 30 2022 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 42.53% year on year, from 41.78% in Mar 31 2022.

In the Healthcare sector 74 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 350, from total ranking in previous quarter at 420.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 112
Healthcare Sector # 75
Overall # 350

Revenue TTM Y/Y Growth Statistics
High Average Low
112.66 %
63.57 %
41.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 112
Sector # 291
S&P 500 # 2109




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GBT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2022
Hims and Hers Health Inc 87.11%$ 87.114 millions
Ufp Technologies Inc 86.25%$ 86.246 millions
Motus Gi Holdings Inc 85.00%$ 85.000 millions
2seventy Bio Inc 83.98%$ 83.979 millions
Agile Therapeutics Inc79.41%$ 79.409 millions
Precision Optics Corporation Inc 79.31%$ 79.313 millions
Docgo Inc 76.12%$ 76.116 millions
Karyopharm Therapeutics Inc 75.56%$ 75.563 millions
Adaptimmune Therapeutics Plc75.39%$ 75.394 millions
Icu Medical Inc74.40%$ 74.400 millions
Mymetics Corporation73.70%$ 73.702 millions
Bionano Genomics Inc 72.98%$ 72.977 millions
Inspire Medical Systems inc 72.56%$ 72.560 millions
Solid Biosciences Inc 71.65%$ 71.647 millions
Senti Biosciences Holdings Inc 71.25%$ 71.248 millions
Petros Pharmaceuticals inc 70.35%$ 70.349 millions
Electrocore Inc 69.91%$ 69.914 millions
Collegium Pharmaceutical Inc 68.39%$ 68.389 millions
Biofrontera Inc 67.86%$ 67.857 millions
Scienture Holdings Inc 67.04%$ 67.044 millions
Abcellera Biologics Inc 66.11%$ 66.107 millions
Therapeutic Solutions International Inc 65.28%$ 65.283 millions
Neptune Wellness Solutions Inc 61.45%$ 61.455 millions
Armata Pharmaceuticals Inc 61.22%$ 61.216 millions
Innovative Eyewear Inc 61.21%$ 61.213 millions
Cvrx inc 61.10%$ 61.095 millions
Volitionrx Limited60.41%$ 60.407 millions
Twist Bioscience Corporation60.24%$ 60.240 millions
G1 Therapeutics Inc 60.10%$ 60.100 millions
Mirum Pharmaceuticals Inc 58.95%$ 58.945 millions


About Global Blood Therapeutics Revenue Growth Rates (GBT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Global Blood Therapeutics Inc (CIK 1629137).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-22-015231
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Global Blood Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.